Spongiform encephalopathies, which are slow neurodegenerative diseases, are caused by proteinaceous infectious particles termed prions. Unlike conventional viruses, prions have no virion structure or genome, elicit no immune response, and are extremely resistant to inactivation by heat, disinfectants, and radiation (Table 1). Prion diseases can be sporadic, genetic, or transmitted and acquired (like a virus). After long incubation periods, these agents cause damage to the central nervous system, leading to subacute spongiform encephalopathy. The long incubation period, which can last 30 years in humans, has made the study of these agents difficult.

Table1. Comparison of Classic Viruses and Prions
Acquired (by infection) human prion diseases include kuru, Creutzfeldt-Jakob disease (CJD), and variant CJD (vCJD). Genetic and sporadic prion diseases include CJD, Gerstmann-Sträussler-Scheinker (GSS) syndrome, and fatal familial insomnia (FFI). Although rare diseases, sporadic occurrences of CJD and FFI occur more commonly (85% to 90% of prion disease cases) than genetic (10% to 15%) or acquired (1% to 3%). The animal diseases include scrapie, bovine spongiform encephalopathy (BSE; [“mad cow disease”]), chronic wasting disease (in mule, deer, and elk), and transmissible mink encephalopathy (Box 1).

Box1. Prion Diseases.
Carlton Gajdusek won the Nobel Prize in 1976 for showing that kuru has an infectious etiology and for developing a method for analyzing the agent. Stanley Prusiner won the Nobel Prize in 1997 for developing a hamster infection model for the scrapie agent. He and his coworkers were able to purify, characterize, and then clone the genes for the scrapie and other prion agents and show that the disease related prion protein is sufficient to cause disease.
Structure and Physiology
The prion is an infectious protein called scrapie-like prion protein (PrPSc), which is protease resistant, hydrophobic, forms fibrillar aggregates, and lacks nucleic acids. The PrPSc is an alternate conformation of a normal cell surface glycoprotein termed cellular prion protein (PrPC) (27,000 30,000 Da). The human version of the PrPC is encoded on chromosome 20 within the PRNP gene. It is highly expressed in neurons and hematopoietic stem cells and their progeny. PrPC is glycosylated and is concentrated in lipid raft regions of the cell membrane surface where it is held by a linkage between its terminal serine and a special lipid called glycophosphatidylinositol (GPI-linked protein). The PrPC is readily internalized and cleaved or recycled. It or its pieces interacts with and modulates the function of numerous membrane proteins in the brain and eye, including pre- and post- synaptic ion channels and neurotransmitter receptors. Mice lacking the PrPC appear normal but have defects in copper, zinc, iron, calcium, and lactate metabolism and deficits in neurite outgrowth, sleep, synaptic transmission, and memory formation upon aging.
Binding to PrPSc changes the conformation of the PrPC protein, which is rich in α-helical configuration to a β-sheet enriched form to produce the aberrant protein termed PrPSc, which builds a fibril (Table 56.2). In contrast to PrPC, the PrPSc is protease resistant, aggregates into amyloid rods (fibrils), and can be released to become cell free.
The current theory to explain how an aberrant protein could cause disease is called template-mediated protein refolding or the seeding–nucleation model. A linear aggregate of PrPSc binds to an anionic structure on the cell surface, such as a glycosaminoglycan, and the normal PrPC on the cell surface. This causes the PrPC to refold, acquire the structure of PrPSc, and join the chain. Binding to the PrPSc forces the α-helical structure of the PrPC to change to a more β-pleated sheet structure of the PrPSc. The PrPSc acts as a template to transmit its conformation onto each PrPC to which it binds and then onto subsequent PrPC to create a chain of PrPScs. When the string of PrPSc breaks, it creates new primers on which more prions can be built. The PrPC continue to be made by the cell, and as they bind to the PrPSc primers, the cycle continues. As a host protein, the PrPSc does not elicit an immune response in patients with the spongiform encephalopathies.
Different strains of PrPSc occur because of mutations to alter the amino acid sequence of the PrPC (genetic) or because of self-perpetuating alternative folding patterns of the protein (sporadic or acquired). Specific mutations at codon 129 are especially important to determine the severity of CJD. Conformational rather than genetic mutation is another property that distinguishes prions from viruses. The different conformational strains can have different properties and varying disease aspects (e.g., incubation period).
Aggregation of other proteins into prions or prion-like structures may cause or contribute to human diseases such as Alzheimer disease, Huntington disease, and Parkinson disease.
Pathogenesis
Prion infection can occur by ingestion, penetration through cuts in the skin, or by direct infection of the brain or neuronal tissue with prion-containing tissue. After uptake, the prions accumulate in highly enervated secondary lymphoid tissue in follicular dendritic cells and B cells and then travel up neurons to the central nervous system and the brain. They are also found in other cell types, including skin.
Spongiform encephalopathy describes the appearance of the vacuolated neurons, as well as their loss of function and a lack of an immune response or inflammation (Box 2). The formation of amyloid-containing plaques and fibrils, a proliferation and hypertrophy of astrocytes, and vacuolation of neurons and adjacent glial cells are observed (Fig. 1). The PrPSc reaches high concentrations in the brain and is taken up by neurons and phagocytic cells but is difficult to degrade, which is a feature that may contribute to the vacuolation of brain tissue. The shedding, build-up of aggregates, and protease resistance of the prion also detract from the normal functions of the protein. Prions can also be isolated from tissue other than the brain, but only the brain shows any pathologic changes. No inflammation or immune response to the agent is generated, distinguishing this disease from classic viral encephalitis. Protein markers (tau protein or 14-3-3 brain protein) can be detected in the CSF of symptomatic persons, but this is not specific to prion disease.

Box2. Pathogenic Characteristics of Prions

Fig1. Template-mediated protein refolding model for proliferation of prions. PrPC is a normal cellular protein that is anchored in the cell membrane by phosphatidylinositol glycan. PrPSc is a hydrophobic fibrillar protein that aggregates with itself and with PrPC on the cell sur face into clumps (1). PrPC acquires the conformation of PrPSc (2). The cell synthesizes new PrPC (3), and a chain is built along cell surface anionic glycosaminoglycans (4). The chain breaks on phagocytosis or from shear forces and releases PrPSc aggregates that act like seed crystals to start the cycle over. A form of PrPSc is internalized by neuronal cells and accumulates (5). Other models have been proposed.
The incubation period for CJD and kuru may be as long as 30 years, but once the symptoms become evident, disease progresses rapidly and death usually occurs within a year.
Epidemiology
CJD is transmitted predominantly by (1) injection, (2) transplantation of contaminated tissue (e.g., corneas), (3) contact with contaminated medical devices (e.g., brain electrodes), and (4) food (Box 3). CJD usually affects persons older than 50 years. CJD, FFI, and GSS syndrome are also inheritable, and families with genetic histories of these dis eases have been identified. The diseases are rare but occur worldwide.

Box3. Epidemiology of Disease Caused by Prions
Kuru was limited to a very small area of the New Guinea highlands. The name of the disease means “shivering” or “trembling,” and the disease was related to the cannibalistic practices of the Fore tribe of New Guinea. Before Gajdusek intervened, it was the custom of these people to eat the bodies of their deceased kinsmen. When Gajdusek began his study, he noted that women and children, in particular, were the most susceptible to the disease, and he deduced that the reasons were that the women and children prepared the food, and they were given the less desirable viscera and brains to eat. Their risk for infection was higher because they handled the contaminated tissue, making it possible for the agent to be introduced through the conjunctiva or cuts in the skin. In addition, they ingested the neural tissue, which contains the highest concentrations of the kuru agent. Cessation of this cannibalistic custom has stopped the spread of kuru.
An epidemic of BSE (mad cow disease) in 1980 in the United Kingdom and the unusual incidence of a more rapidly progressing CJD in younger people ( <45 years) in 1996 prompted concern that contaminated beef was the source of this new variant of CJD (termed vCJD). Infection of cattle was most likely caused by the use of contaminated animal by-products (e.g., sheep entrails, brains) as a protein supplement in cattle feed. Ingestion of contaminated beef is likely to be the cause of 153 cases of vCJD, more than 98% of which have occurred in the United Kingdom.
Clinical Syndromes
The prion agents cause a progressive, degenerative neuro logic disease with a long incubation period, but with rapid progression to death after the onset of symptoms (Fig. 2; Box 4). The spongiform encephalopathies are characterized by a loss of muscle control, shivering, myoclonic jerks and tremors, loss of coordination, rapidly progressive dementia, and death.

Fig2. Progression of transmissible Creutzfeldt-Jakob disease.

Box4. Clinical Summaries
The cases in Box 4 show the classic progression of CJD and vCJD. CJD progresses through five stages: (1) incubation (6+ years), (2) prodromal fatigue and difficulty concentrating (18 months), (3) progressive neurologic decline (9 months), (4) late neurologic phase (4 months), and (5) terminal phase. vCJD has a much shorter incubation period and progresses much quicker.
Laboratory Diagnosis
There are no methods for directly detecting prions in tis sue, and there is no serologic response. The initial diagnosis must be made on clinical grounds. Initial confirmation of the diagnosis can be made by magnetic resonance imaging, detection of elevated levels of 14-3-3 protein or tau protein in CSF, or a proteinase K–resistant form of PrP in a Western blot using antibody to PrP in a tonsil biopsy. Immunoblot analysis and ELISA of treated prion proteins can distinguish the PrPSc from the normal protein in samples that can be taken from the patient’s tonsils (or at autopsy, from the brain). The ability of PrPSc to initiate the polymerization of normal PrP is utilized in the protein-misfolding cyclic assay (PMCA) to amplify the number of PrPSc units and can be used to detect the presence of prions. The real-time quaking-induced conversion assay (RT-QuIC) is the test of choice, if available, and tests CSF or nasal-brushing specimens. The test measures the aggregation of PrP into prion fibrils by enhancement of the fluorescence of thioflavin T. At autopsy, the characteristic amyloid plaques, spongiform vacuoles, and immunohistologically detected PrP can be observed.
Treatment, Prevention, and Control
No treatment exists for kuru or CJD. The causative agents are also impervious to the disinfection procedures used for other viruses, including formaldehyde, detergents, and ionizing radiation. Autoclaving at 15 psi for 1 hour (instead of 20 minutes) or treatment with 5% hypochlorite solution or 1.0 M sodium hydroxide can be used for decontamination. Because these agents can be transmitted on instruments and brain electrodes, such items should be carefully disinfected before being reused. Because of the long incubation period for prion diseases, identification of infected individuals and prevention of transmission of CJD within transfusions or transplants or by contaminated surgical tools is difficult.
The outbreak of BSE and vCJD in the United Kingdom promoted legislation to ban animal products in livestock feed and encouraged more careful monitoring of cattle. Prion disease has not been a problem in cattle in the United States. Cattle must be younger than 5 years old to minimize the possibility of accumulation of aberrant PrP and so that muscle tissue would have the lowest amount of PrP.